VAR2 Pharmaceuticals

... is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications.

About VAR2 Pharmaceuticals

VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.

The technology is based on groundbreaking discoveries made by researchers at University of Copenhagen, Denmark, in collaboration with partners at University of British Columbia, Canada.

Read more
22 June 2017
Uncategorized
We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prog...
03 May 2017
Uncategorized
As of May 1st,  Dr. Andreas L Norlin has taken up the position as Chief Operating Officer. Andreas comes with a deep knowledge of drug development strategy and execution from more than 20 years in research, pre-clinical and clinical development in academia, biotech and big pharma, most recently...
03 May 2017
Uncategorized

It is with great pleasure that VAR2 Pharmaceuticals can announce that our first patent has been issued by the Australian Government (IP Australia). Key claims on the use of recombinant VAR2CSA for targeting, treating and diagnosing cancer was accepted and issued.

17 April 2017
Uncategorized
Cisplatin is worldwide standard-of-care chemotherapy in muscle-invasive bladder cancer (MIBC). However, many patients develop resistance to cisplatin with no second-line treatment options currently available. A new study published on April 10, 2017 in European Urology demonstrates VAR2-mediated drug...

Our Investors

VAR2 Pharmaceuticals is owned by the inventor group and University of Copenhagen, and we are financed by private investors.

Read More

Want to be a partner?

To discuss a potential partnership opportunity with VAR2 Pharmaceuticals please contact us

Read more